BioCryst prices stock offering at $9.75 per share
BioCryst
Related Blog Posts
- Delay in H1N1 vaccine production could boost BioCryst
- Durham firm develops intravenous H1N1 vaccine
- Pharmaceutical firm with lab in Durham wins $77.2M federal contract for flu drug development
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter
Associated Press
BIRMINGHAM, Ala. — Flu-drug developer BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) priced its 5 million common stock share offering at $9.75 per share.
BioCryst has a lab in Durham, N.C.
On Thursday after the markets closed, the company estimated gross proceeds of $48.8 million. The banks underwriting its offer will have the option to buy another 750,000 shares to cover over-allotments in the following month. If all 5.75 million shares are sold, BioCryst's share count will rise almost 15 percent.
BioCryst's most advanced drug candidate is peramivir, a flu drug intended to be given by IV to patients who are too sick to take an oral dose. Peramivir has been approved as an emergency treatment for swine flu, but clinical testing against seasonal flu is expected to last until 2011.
Shares of the company fell 69 cents, or 6.6 percent, to $9.71 in morning trading.
Copyright 2012 by The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Featured
E-mail Preferences
The Skinny
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming